Enjaymo (sutimlimab-jome) is an intravenous monoclonal antibody classical complement inhibitor indicated to decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease.
If you have a Hayes login, click here to view the full report on the Knowledge Center.